Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization

Stuart S. Winter; Kimberly P. Dunsmore; Meenakshi Devidas; Brent L. Wood; Natia Esiashvili; Zhiguo Chen; Nancy Eisenberg; Nikki Briegel; Robert J. Hayashi; Julie M. Gastier‐Foster; Andrew J. Carroll; Nyla A. Heerema; Barbara L. Asselin; Paul S. Gaynon; Michael J. Borowitz; Mignon L. Loh; Karen R. Rabin; Elizabeth A. Raetz; Patrick A. Zweidler‐McKay; Naomi Winick; William L. Carroll; Stephen P. Hunger

doi:10.1200/jco.2018.77.7250

Abstract

This is the authors' abstract. We don't add key points for this paper.

AALL0434 established that ABFM with C-MTX was superior to ABFM plus HDMTX for T-ALL in approximately 90% of patients who received CRT, with later timing for those receiving HDMTX.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Winter et al. (2018) studied this question.

synapsesocial.com/papers/69d819f9b5518339b2ae2cc1 https://doi.org/10.1200/jco.2018.77.7250

View at Publisher

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

AALL0434 established that ABFM with C-MTX was superior to ABFM plus HDMTX for T-ALL in approximately 90% of patients who received CRT, with later timing for those receiving HDMTX.

Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization

Abstract

Ask about this paper

Discussion

Cite This Study

Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading